Restructuring of the Immune Contexture Improves Checkpoint Blockade Efficacy in Murine Lung Cancer

Therapeutic options for non-small cell lung cancer (NSCLC) treatment have changed dramatically in recent years with the advent of novel immunotherapeutic approaches. Among these, immune checkpoint blockade (ICB), using monoclonal antibodies, has shown tremendous promise in a small proportion of patients. In order to better predict patients that will respond to ICB treatment, biomarkers such as…

Read the full article here

Source: bioRxiv
Categories: General Medicine Journals and Societies, Latest Headlines
Tags:
Tweets with this article
bioRxiv
Restructuring of the Immune Contexture Improves Checkpoint Blockade Efficacy in Murine Lung Cancer https://t.co/o0000TxDql #bioRxiv

Related Articles